Literature DB >> 31485383

The Role of Tumor Necrosis Factor Alpha (TNFα)in Hearing Loss and Vestibular Schwannomas.

Yin Ren1,2, Konstantina M Stankovic1,2,3,4.   

Abstract

PURPOSE OF REVIEW: The aim of this review is to highlight relevant literature on the role of tumor necrosis factor alpha (TNFα) in sensorineural hearing loss (SNHL) and vestibular schwannomas (VS). RECENT
FINDINGS: A comprehensive review of publically available databases including PubMed was performed. The mechanism by which hearing loss occurs in VS is still unknown and likely multifactorial. Genetic differences between VSs and tumor secreted proteins may be responsible, at least in part, for VS-associated SNHL. TNFα has pleotropic roles in promoting inflammation, maintaining cellular homeostasis, inducing apoptosis, and mediating ototoxicity in patients with sporadic VS. TNFα-targeted therapies have shown efficacy in both animal models of sensorineural hearing loss and clinical trials in patients with immune-mediated hearing loss. Efforts are underway to develop novel nanotechnology-based methods to target TNFα and other pathogenic molecules in VS.
SUMMARY: Development of molecularly targeted therapies against TNFα represents an important area of research in ameliorating VS-associated hearing loss.

Entities:  

Keywords:  TNF alpha; TNFα; hearing loss; inflammation; nanotechnology; vestibular schwannoma

Year:  2018        PMID: 31485383      PMCID: PMC6724722          DOI: 10.1007/s40136-018-0186-4

Source DB:  PubMed          Journal:  Curr Otorhinolaryngol Rep


  82 in total

1.  Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.

Authors:  Stanley Cohen; Angela Shoup; Michael H Weisman; Jeffrey Harris
Journal:  Otol Neurotol       Date:  2005-09       Impact factor: 2.311

2.  Vibration induced hearing loss in guinea pig cochlea: expression of TNF-alpha and VEGF.

Authors:  Jing Zou; Ilmari Pyykkö; Päivi Sutinen; Esko Toppila
Journal:  Hear Res       Date:  2005-04       Impact factor: 3.208

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

4.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

5.  Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.

Authors:  Eric L Matteson; Hyon K Choi; Dennis S Poe; Christopher Wise; Val J Lowe; Thomas J McDonald; Mahboob U Rahman
Journal:  Arthritis Rheum       Date:  2005-06-15

6.  Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.

Authors:  M U Rahman; D S Poe; H K Choi
Journal:  Otol Neurotol       Date:  2001-09       Impact factor: 2.311

7.  Proinflammatory cytokines expression in noise-induced damaged cochlea.

Authors:  Masato Fujioka; Sho Kanzaki; Hirotaka James Okano; Masatsugu Masuda; Kaoru Ogawa; Hideyuki Okano
Journal:  J Neurosci Res       Date:  2006-03       Impact factor: 4.164

8.  Use of methotrexate for autoimmune hearing loss.

Authors:  E L Matteson; O Tirzaman; G W Facer; D A Fabry; J Kasperbauer; C W Beatty; T J McDonald
Journal:  Ann Otol Rhinol Laryngol       Date:  2000-08       Impact factor: 1.547

9.  Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation.

Authors:  Hitoshi Satoh; Gary S Firestein; Peter B Billings; Jeffrey P Harris; Elizabeth M Keithley
Journal:  Laryngoscope       Date:  2002-09       Impact factor: 3.325

10.  Expression of angiogenic growth factors in acoustic neurinoma.

Authors:  Jürgen Brieger; Anan Bedavanija; Hans-Anton Lehr; Jan Maurer; Wolf J Mann
Journal:  Acta Otolaryngol       Date:  2003-12       Impact factor: 1.494

View more
  9 in total

Review 1.  Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery: Otologists' Perspective from Bedside to Bench.

Authors:  Makoto Hosoya; Takeshi Wakabayashi; Koichiro Wasano; Takanori Nishiyama; Nobuyoshi Tsuzuki; Naoki Oishi
Journal:  Diagnostics (Basel)       Date:  2022-04-21

2.  Cytokine Levels in Inner Ear Fluid of Young and Aged Mice as Molecular Biomarkers of Noise-Induced Hearing Loss.

Authors:  Lukas D Landegger; Sasa Vasilijic; Takeshi Fujita; Vitor Y Soares; Richard Seist; Lei Xu; Konstantina M Stankovic
Journal:  Front Neurol       Date:  2019-09-11       Impact factor: 4.003

3.  Editorial: Neuroimmunology of the Inner Ear.

Authors:  Paola Perin; Franca Marino; Isabel Varela-Nieto; Agnieszka J Szczepek
Journal:  Front Neurol       Date:  2021-02-09       Impact factor: 4.003

4.  Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing.

Authors:  Eric Nisenbaum; Carly Misztal; Mikhaylo Szczupak; Torin Thielhelm; Stefanie Peña; Christine Mei; Stefania Goncalves; Olena Bracho; Ruixuan Ma; Michael E Ivan; Jacques Morcos; Fred Telischi; Xue-Zhong Liu; Cristina Fernandez-Valle; Christine T Dinh
Journal:  OTO Open       Date:  2021-11-23

5.  Genome-wide association study identifies new loci associated with noise-induced tinnitus in Chinese populations.

Authors:  Chengyong Xie; Yuguang Niu; Jie Ping; Yahui Wang; Chenning Yang; Yuanfeng Li; Gangqiao Zhou
Journal:  BMC Genom Data       Date:  2021-09-06

6.  Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation.

Authors:  Alyssa Brown; Samuel Early; Sasa Vasilijic; Konstantina M Stankovic
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

7.  Up-Regulated Expression of Interferon-Gamma, Interleukin-6 and Tumor Necrosis Factor-Alpha in the Endolymphatic Sac of Meniere's Disease Suggesting the Local Inflammatory Response Underlies the Mechanism of This Disease.

Authors:  Chao Huang; Qin Wang; Xueying Pan; Wei Li; Wei Liu; Wenqi Jiang; Li Huang; Anquan Peng; Zhiwen Zhang
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

Review 8.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

9.  Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Authors:  Limeng Wu; Sasa Vasilijic; Yao Sun; Jie Chen; Lukas D Landegger; Yanling Zhang; Wenjianlong Zhou; Jun Ren; Samuel Early; Zhenzhen Yin; William W Ho; Na Zhang; Xing Gao; Grace Y Lee; Meenal Datta; Jessica E Sagers; Alyssa Brown; Alona Muzikansky; Anat Stemmer-Rachamimov; Luo Zhang; Scott R Plotkin; Rakesh K Jain; Konstantina M Stankovic; Lei Xu
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 19.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.